INDIANAPOLIS, Oct. 28,
2024 /PRNewswire/ -- The board of directors of Eli
Lilly and Company (NYSE: LLY) has declared a dividend for the
fourth quarter of 2024 of $1.30 per
share on outstanding common stock.
The dividend is payable on Dec. 10,
2024, to shareholders of record at the close of business on
Nov. 15, 2024.
About Lilly
Lilly is a medicine company turning
science into healing to make life better for people around the
world. We've been pioneering life-changing discoveries for nearly
150 years, and today our medicines help tens of millions of people
across the globe. Harnessing the power of biotechnology, chemistry
and genetic medicine, our scientists are urgently advancing new
discoveries to solve some of the world's most significant health
challenges: redefining diabetes care; treating obesity and
curtailing its most devastating long-term effects; advancing the
fight against Alzheimer's disease; providing solutions to some of
the most debilitating immune system disorders; and transforming the
most difficult-to-treat cancers into manageable diseases. With each
step toward a healthier world, we're motivated by one thing: making
life better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news. F-LLY
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements (as that term is defined in the Private Securities
Litigation Reform Act of 1995) about expected dividend payments and
reflects Lilly's current beliefs and expectations. However, there
are significant risks and uncertainties in pharmaceutical research
and development, as well as in business development activities and
capital allocation strategies related to the company's business and
actual results may differ materially due to various factors. For
further discussion of risks and uncertainties relevant to Lilly's
business that could cause actual results to differ from Lilly's
expectations, see Lilly's Form 10-K and Form 10-Q filings with the
United States Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements to reflect events after the date of this release.
|
Refer
to:
|
Jordan Bishop;
jordan.bishop@lilly.com; 317-374-1878 (Media)
|
|
|
Joe Fletcher;
jfletcher@lilly.com; 317-296-2884 (Investors)
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-declares-fourth-quarter-2024-dividend-302288753.html
SOURCE Eli Lilly and Company